By Elric Langton | 31 March 2022
On track to commence LPS human challenge clinical trial in June 2022
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF) shares are up 5% to 7p bid as I write on the back of the announcement it has signed a Clinical Trial Agreement with the Centre for Human Drug Research (CHDR) in the Netherlands for the completion of bacterial lipopβ¦